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Hodgkin lymphoma (HL) is a lymphoid neoplasm that normally originates from 
germinal centre B-cells. It is the most common cancer in adolescents aged 15–
19 years, and the sixth most common in children aged 0–14 years 
(http://www.cancer.org/Research/CancerFactsStatistics/CancerFactsFigures2
014/cancer-facts-and-figures-2014.pdf) The global annual incidence of HL in all 
age groups is 3 in 100 000, and it represents about 30% of lymphomas (Stein, 
2008). HL is divided into classical Hodgkin lymphoma (CHL), which accounts 
for 95% of cases, and nodular lymphocyte predominant Hodgkin lymphoma 
accounting for the remaining 5%. A particular characteristic of CHL is that the 
clonal tumour cells, the so-called Hodgkin-Reed-Sternberg (HRS) cells, 
constitute only about 1% of the tumour mass, the majority of the tissue being 
composed of benign immune and inflammatory cells. Because of this, 
identification of somatic mutations that might play a role in CHL tumourigenesis 
is challenging. 
 
The aetiology of CHL is not completely understood. Epstein–Barr virus (EBV) 
infection is associated with CHL, with about 40% of CHL cases expressing 
EBV-encoded RNAs, and the role of EBV in HL pathogenesis is further 
supported by molecular biology studies (Kuppers, 2009). However, given that 
EBV is one of the most common viruses, the role of genetic factors in HL 
susceptibility should also be acknowledged. The familial clustering of CHL has 
been reported (Goldin et al, 2004), however, a germline translocation affecting 
the KLHDC8B gene is currently the only known candidate for a penetrant CHL 
predisposing mutation (Salipante et al, 2009). 
 
In this work, we studied a family of Middle Eastern origin whose clinical 
description has been reported earlier (Kamper et al, 2005). Three out of five 
children were diagnosed with EBV-positive CHL within a 6-year period (Fig 1). 
The index case, Patient I, is a male diagnosed with nodular sclerosis CHL 
(NSCHL) at the age of 5 years, Patient II is a female diagnosed with NSCHL at 
12 years of age and Patient III is a male diagnosed with mixed cellularity CHL 
when aged 12 years. The affected siblings share human leucocyte antigen 
class I haplotypes A26B38;A9B5 and their tumour cells were EBV-positive. 
Based on serology in February 2012, the unaffected siblings also had a prior 
EBV infection. 
 
Figure 1. The family pedigree and ACAN c.2836_2892del status. 
 
To identify the putative CHL predisposing genetic defects, we sequenced the 
exomes from the affected siblings' blood samples using 101 bp paired-end 
reads. Using a control set of 3891 exomes and genomes (in-house Finnish 
patients with other phenotypes and multiethnic public datasets), and accepting 
only variants shared by affected individuals, resulted in 35 variants. Then 35 
genes containing these variants were then prioritized (i.e. their relatedness to 
lymphoma was assessed) and the deleteriousness of each variant was 
predicted computationally. Applying the selection criteria (Data S1) resulted in 
ten missense and three other type CHL candidate variants (Table 1). The full 
list of shared variants can be found in Table SI and the list of HL-associated 
genes used in prioritization in Table SII. 
 
Table 1. Candidate classical Hodgkin lymphoma predisposing variants. 
 
The only homozygous variant was a cluster of closely located single nucleotide 
variants in the ACAN gene. Interestingly, Sanger sequencing of the region 
revealed that the aberrant signal arose from a homozygous 57-base pair in-
frame deletion c.2836_2892del, leading to a deletion of 19 amino acids (Figure 
S1). Both parents and one unaffected child were found to be heterozygous for 
the deletion, and the other unaffected sibling displayed wild type ACAN (Fig 1). 
ACAN encodes a proteoglycan called aggrecan, which is an essential element 
of the extracellular matrix in cartilaginous tissue. It contains a long tandem 
repeat sequence consisting of 19 repeats of 19-amino acid motif. The deletion 
identified in ACAN removes part of the repeat sequence as well as nine amino 
acids from the unique sequence. ACAN has not been associated with 
tumourigenesis or tumour predisposition but recent research has suggested 
that noncellular tumour microenvironment components may promote the 
oncogenic effects of EBV (Cader et al, 2013). 
 
Because the pedigree structure is compatible with a recessive mode of 
inheritance, we determined the ratio of homozygous and heterozygous variants 
of the affected siblings (Table SIII), to establish whether it could provide support 
for the trait to be recessive. For controls, the same ratio was also determined 
in 12 randomly selected Finnish in-house samples. Indeed, homozygosity was 
shown to be higher in the affected individuals than in Finnish controls, which is 
noteworthy because of the inbreeding in the Finnish population. 
 
Besides the ACAN deletion, the candidate variant set contains a nonsense 
variant in KIAA0141, and a removal of stop codon in LY75-CD302. LY75-
CD302 is a fusion protein resulting from read-through transcription between the 
lymphocyte antigen 75 (LY75) and CD302 molecule (CD302) genes, and 
interestingly, was originally identified in HRS cell lines (Kato et al, 2003). The 
stop codon removal was found to be present in all affected individuals and their 
unaffected father. The change results in addition of 22 amino acids to LY75-
CD302 and CD302 proteins. KIAA0141 is a death-associated protein 3 binding 
apoptosis signal enhancer (Harada et al, 2010). The observed change results 
in a premature stop in the last exon 12, which truncates the protein 13 amino 
acids before the reference stop codon. 
 
Of the 10 genes containing missense-type candidate variants (TNS1, USP10, 
AFTPH, IPO9, CCDC64, MIEF1, OR52N2, VPS36, FAT2 and KLHL35; listed 
in descending prioritization order), USP10 seems most interesting, based on its 
function. It is a deubiquitinating protease, acting as a regulator of TP53 in DNA 
damage response and tumour development (Jochemsen & Shiloh, 2010). Gene 
descriptions for the remaining candidates can be found in Table SI. 
 
The candidate genes above provide a platform for validation studies in 
extended sets of familial CHL samples. Robust identification of additional 
mutations in families with this intriguing disease-susceptibility phenotype would 
be a breakthrough in CHL risk prediction and provide valuable clues to the 
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* - - 89 0,49 het 10
50            
¹ Rank according to sum of ToppGene and 
Endeavour ranks (see Table S1) 
      
2These are averages of three samples; variant quality scores are 
by GATK UnifiedGenotyper 
     
- Prediction scores could only 
be calculated for SNPs 
        
* Endeavour did not recognize Ensembl gene ID ofLY75-CD302, so 
prioritization could only be done by ToppGene 
    
** this information forACANis not available, since the homozygous deletion 
was discovered using Sanger sequencing 
    
 
Table 1. Candidate classical Hodgkin lymphoma predisposing variants. 
 
 
 
